New diagnostic and therapeutic tools
against multidrug resistant tumours

We aim to improve both
the diagnosis and therapy
of multidrug resistant (MDR)
solid tumours.

Welcome!

STRATAGEM contributes to Covid-19 research

Fighting together
against multidrug
resistant tumours

Special
issues
edited by
our scientists

Identification of new biomarkers and therapeutic targets for MDR tumours

Synthesis and nanodelivery strategies for new therapeutic tools against MDR tumours

Efficacy validation of new therapeutic tools against pre-clinical models of MDR tumours

Pharmacokinetics and ADMET of the new therapeutic tools; safety of the targets

Forum

DRU Highlights

Our paper The multi-factorial nature of clinical multidrug resistance in cancer was selected by ASPIC (Portuguese Association of Cancer Research),…

Read more...